📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.75
SENTIMENT
NEUTRAL
TOTAL VIEWS
7
CAPR Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 4 ARTICLES
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)
Capricor Therapeutics (CAPR) faces a significant headwind following a downgrade to Sell, driven by FDA efficacy doubts surrounding its...
Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know (NASDAQ:CAPR)
Capricor (CAPR) experienced a sharp 65% equity decline following negative FDA Advisory Committee feedback on deramiocel's efficacy...
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics (CAPR) has scheduled an FDA Advisory Committee meeting for July 29, 2026, to review a Biologics License...
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Capricor Therapeutics (CAPR) announced positive five-year efficacy and safety data for deramiocel in Duchenne muscular dystrophy, a...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice